Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis

Kakuhiro Yamaguchi, Hiroshi Iwamoto, Witold Mazur, Shinichiro Miura, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Shintaro Miyamoto, Taku Nakashima, Shinichiro Ohshimo, Kazunori Fujitaka, Hironobu Hamada and Noboru Hattori

Abstract

Background: The endogenous secretory receptor for advanced glycation end products (esRAGE) is a soluble isoform produced by alternative splicing of the RAGE gene. The isoform has anti-inflammatory properties due to its inhibition of the RAGE/ligand interaction and is reduced in the lung tissue of patients with idiopathic pulmonary fibrosis (IPF). This study aimed to investigate the association of esRAGE serum and bronchoalveolar lavage fluid (BALF) levels with progression of IPF.

Methods: This study included 79 IPF patients and 90 healthy controls. IPF and control serum esRAGE levels were compared, and the correlation between serum and BALF esRAGE levels was analyzed in 57 IPF patient samples. We also investigated the relationship of esRAGE serum and BALF levels with prognoses and lung function parameters in patients with IPF.

Results: Serum esRAGE levels in IPF patients were significantly lower than those in healthy controls (162.0 ± 102.4 ng/ml and 200.7 ± 107.3 ng/ml, p = 0.009), although the baseline characteristics of age and smoking history were not matched. Serum levels of esRAGE were correlated with BALF esRAGE levels (r_s = 0.317). The BALF esRAGE levels were also correlated with diffusion capacity for carbon monoxide (r_s = 0.406). A Kaplan-Meier curve analysis and univariate/multivariate Cox hazard proportion analysis revealed that lower levels of esRAGE in blood and BALF were significantly associated with poorer prognoses in patients with IPF.

Conclusions: Decreased esRAGE levels in BALF and blood were associated with poor prognoses in patients with IPF. These results suggest that esRAGE could be related to the pathophysiology of IPF and serum esRAGE could be a potential prognostic marker of IPF.

Keywords: esRAGE, IPF, BALF, Serum, Biomarker
Background
The receptor for advanced glycation end-product (RAGE) is a transmembrane receptor that can bind numerous ligands, and the RAGE/ligand interaction results in cellular activation and gene transcription [1, 2]. Although the expression of RAGE is at low levels in the majority of normal tissues, it is abundantly expressed in the normal lung, especially in type 1 pneumocytes [3–5]. Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic lung disease with poor prognosis, characterized by recurrent alveolar epithelial injury followed by aberrant tissue repair and excessive matrix deposition [6, 7]. Previous studies have shown that RAGE expression in lung tissue is reduced in IPF when compared with controls, and functional polymorphism of the RAGE gene is associated with risk of IPF [8–11]. Additionally, in RAGE knockout mice, pulmonary fibrosis is caused by aging and may be further aggravated by exposure to asbestos [12]; therefore, RAGE may play a homeostatic role in the lungs. These observations indicate that decreased expression of RAGE in the lungs is associated with the development and severity of IPF.

Alternative splicing of RAGE gene leads to the formation of endogenous secretory RAGE (esRAGE), which lacks the transmembrane domain but has an extracellular ligand-binding domain; it has anti-inflammatory properties and acts as a decoy neutralizing RAGE-ligands [13–17]. Interestingly, proteomic analysis demonstrated that, compared to control subjects, the expression of esRAGE was reduced in the lung tissue of patients with IPF and not in chronic obstructive pulmonary disease (COPD) [9]. This suggests that esRAGE may be related to the pathophysiology of IPF. On the other hand, there have been no studies investigating the association between circulating esRAGE and the disease severity and prognosis of IPF.

This study aimed to investigate whether esRAGE concentrations in blood and bronchoalveolar lavage fluid (BALF) are associated with the prognoses of IPF, and to explore esRAGE regulatory mechanisms by focusing on RAGE gene polymorphisms. First, we measured esRAGE levels in the serum and BALF and evaluated their correlation. Second, we analyzed the association of esRAGE levels in the serum and BALF with pulmonary function parameters and prognosis in patients with IPF. Additionally, the correlation between esRAGE levels and differential cell counts in the BALF was investigated, because inflammatory cells in the lung are reported to express RAGE [18, 19]. Finally, an exploratory analysis investigated the association of esRAGE concentrations with two RAGE gene polymorphisms: rs1800624 and rs1800625, which influenced the promoter activity of the RAGE gene [20].

Methods
Subjects
A total of 79 IPF patients and 90 healthy control subjects were included in the present study. The patients first visited the Department of Respiratory Medicine in Hiroshima University Hospital (Hiroshima, Japan) from 2003 to 2015, and the diagnosis of IPF was confirmed on retrospective review based on the ATS/ERS criteria [7]. As a result, sixty-six IPF patients were diagnosed with usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT), and 13 IPF patients were diagnosed with possible UIP pattern on HRCT and histological UIP pattern in surgical lung biopsies. Additionally, BALF samples were obtained during bronchoscopy from 57 of the 79 patients with IPF. This study was approved by the Ethics Committee of Hiroshima University Hospital (IRB33 approved in 2001 and M326 approved in 2004), and all participants provided written informed consent.

Serum and BALF measurements and pulmonary function tests
Serum and BALF samples were collected at diagnosis and stored at −80 °C. BALF was obtained under local anesthesia by introducing 50 mL of saline into the lung and promptly drawing it out again via a bronchoscope [21]. These procedures were repeated three times, and, in total, 150 mL of saline was introduced. The target region (determined by the HRCT results) was either the middle lobe or the lingular segment, depending on which was most severely affected. All of the retrieved saline was mixed and centrifuged, and the supernatant was collected. esRAGE levels were measured with a commercially available enzyme-linked immunosorbent assay (ELISA) kits, according to the manufacturer’s instructions (esRAGE ELISA kit, B-Bridge International, Sunnyvale, CA, USA). The esRAGE levels in the serum and BALF were fully within the measurable range; this was confirmed by duplicate analysis.

Pulmonary function variables were measured using spirometry (Chestac-55 V and Chestac-8800, CHEST, Tokyo Japan) in accordance with the American Thoracic Society and the European Respiratory Society recommendations [22].

DNA preparation and genotyping
Peripheral whole venous blood samples were gathered from all participants and stored at −80°C. Genomic DNA was extracted with the phenol-chloroform extraction and ethanol precipitation methods, as previously described [23, 24]. The RAGE gene polymorphisms were genotyped successfully for all patients and healthy controls. The genotypes were determined using a commercially available polymerase chain reaction (PCR) assay.
Each sample contained 10 μl of the PCR mixture, which in turn contained 0.25 μl of TaqMan SNP Genotyping Assay (C_3293837_1, C_8848033_1, C_2412456_10), 1.0 μl of genomic DNA (2.0 g/mL), 3.75 μl of double distilled water, and 5.0 μl of TaqMan Fast Universal PCR Master Mix. All aforementioned PCR mixture and genotyping assay reagents were from Life Technologies Corporation (Carlsbad, CA, USA). The real-time PCR analysis was conducted using the Applied Biosystems 7500 Fast Real-Time PCR System (Life Technologies Corp.).

Statistical analyses
Values were expressed as mean ± standard deviation (SD). Differences between groups were identified using the Mann-Whitney U tests and Pearson’s chi-squared tests. The Spearman’s rank correlation coefficient was calculated to reveal any association of esRAGE BALF levels with esRAGE serum levels, lung function parameters, and differential cell counts in the BALF in patients with IPF. We used receiver operating characteristic (ROC) curve analysis to find the optimal value of serum and BALF esRAGE for predicting 5-year survival in patients with IPF. Survival was calculated with the Kaplan-Meier approach and the log-rank test. The Cox proportional hazards analysis was used to identify significant predictors of IPF prognosis. All p-values < 0.05 were considered significant. All data analyses were performed using JMP statistical software version 14.1.0 (SAS Institute Inc., Cary, NC, USA).

Results
Subject characteristics
Total study population baseline characteristics are shown in Table 1. Patients with IPF in both the serum and BALF analysis groups were significantly older, had higher pack-year smoking histories, and lower forced vital capacity (FVC) than the healthy controls. There were no significant differences in baseline characteristics between the IPF patient serum and BALF groups. Diffusion capacity for carbon monoxide (DLco) was measured in 73 of 79 IPF patients with serum sample and 55 of 57 patients with BALF sample, respectively; this was not correlated with age and smoking history in these patients (data not shown).

Baseline concentrations of esRAGE in blood and BALF
Serum levels of esRAGE in patients with IPF were significantly lower than those in healthy controls (162.0 ± 102.4 ng/ml and 200.7 ± 107.3 ng/ml, respectively, p = 0.009, Fig. 1). However, there was no correlation of esRAGE levels in the serum with lung function parameters (data not shown).
The BALF levels of esRAGE were 219.7 ± 202.7 ng/ml, and positively associated with serum levels of esRAGE in patients with IPF ($r_s = 0.317$, $p = 0.016$; Fig. 2). The BALF levels of esRAGE were significantly correlated with DLco ($r_s = 0.406$, $p = 0.002$; Table 2), but not with FVC and differential cell counts in the BALF.

In this study, the baseline characteristics of age and smoking history were not matched in patients with IPF and control subjects, and therefore we evaluated the association of esRAGE levels in the serum and BALF with these characteristics. There was no significant correlation of esRAGE levels with age and smoking history in patients with IPF (data not shown).

Furthermore, there was no significant difference in the blood and BALF esRAGE levels between patients with or without the minor allele of the RAGE gene polymorphisms (rs1800624 and rs1800625) (Additional file 1: Table S1).

**Prognostic value of esRAGE in blood and BALF**

In patients with IPF, the median observation period was 42.2 months. The optimal cut-off levels for predicting 5-year survival rates were 95 ng/ml in the serum analysis group and 125 ng/ml in the BALF analysis group, as determined by the ROC curves with area under the curve (AUC) values of 0.716 and 0.717, respectively. The Kaplan-Meier method and log-rank test showed that the survival rates were significantly lower in patients with lower levels of esRAGE in both the serum and BALF.

![Graph showing association between BALF and serum levels of esRAGE](image)

**Table 2** Association of BALF esRAGE levels with pulmonary function parameters and differential cell counts in BALF ($n = 57$)

| Variables                          | $r_s$  | $P$-value |
|-----------------------------------|--------|-----------|
| Pulmonary function parameters     |        |           |
| FVC, % predicted                  | −0.025 | 0.853     |
| DLco, % predicted                 | 0.406  | 0.002*    |
| Differential cell counts in BALF  |        |           |
| Total cell, $10^4$/ml             | −0.002 | 0.990     |
| Macrophage, %                     | 0.060  | 0.667     |
| Macrophage, $10^4$/ml             | 0.016  | 0.907     |
| Lymphocyte, %                     | 0.125  | 0.369     |
| Lymphocyte, $10^4$/ml             | 0.160  | 0.247     |
| Neutrophil, %                     | −0.049 | 0.727     |
| Neutrophil, $10^4$/ml             | −0.022 | 0.877     |
| Eosinophil, %                     | −0.117 | 0.400     |
| Eosinophil, $10^4$/ml             | −0.063 | 0.650     |

* $p < 0.05$ Spearman’s rank correlation coefficient

*DLco was measured in 55 of 57 patients with IPF

esRAGE endogenous secretory receptor for advanced glycation end products, BALF bronchoalveolar lavage fluid, DLco diffusing capacity for carbon monoxide, FVC forced vital capacity
analysis groups ($p = 0.011$ and $p = 0.003$, respectively; Fig. 3). Univariate and multivariate Cox proportional hazards analysis revealed that lower levels of esRAGE were significantly correlated with poorer prognoses in patients with IPF, in both the serum and BALF analysis groups (Table 3).

**Discussion**

This study demonstrated that serum esRAGE levels in IPF patients were significantly lower than those in healthy controls and that lower levels of serum esRAGE were associated with a poorer prognosis in IPF patients. Remarkably, decreased levels of BALF esRAGE were associated not only with decreased levels of serum esRAGE but also with lower DLco and poorer prognosis. These data could suggest that decreased serum levels of esRAGE may be associated with a pro-inflammatory condition of the lungs, which in turn decrease the levels of esRAGE in the BALF and result in a poor prognosis.

We found that lower levels of esRAGE in blood and BALF were independently associated with a poor prognosis in patients with IPF. RAGE-ligands such as HMGB1 and S100 proteins have been associated with the progression of IPF. In earlier reports, it has been shown that BALF and serum levels of HMGB1 are elevated in patients with IPF and that elevated serum

![Fig. 3](image)

**Table 3** Predicting value for 5-year mortality in IPF patients assessed by Cox proportional hazards model

| Variables | Serum (n = 79) | BALF (n = 57) |
|-----------|---------------|--------------|
|           | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis |
|           | HR      | 95% CI    | p-value | HR      | 95% CI    | p-value | HR      | 95% CI    | p-value |
| Age, years | 0.99    | 0.95–1.04 | 0.680   | –       | –       | –       | 1.02    | 0.97–1.08 | 0.474   |
| Sex, Male/Female | 1.16 | 0.27–4.98 | 0.648   | –       | –       | –       | 0.94    | 0.91–0.98 | < 0.001* |
| Smoking history, pack-years | 1.00 | 0.98–1.01 | 0.825   | –       | –       | –       | 0.99    | 0.98–0.99 | 0.019*   |
| FVC, % predicted | 0.94 | 0.91–0.98 | < 0.001* | 0.94    | 0.91–0.98 | 0.002* | 0.96    | 0.93–0.99 | 0.009*   |
| Serum esRAGE, ng/ml | 0.99    | 0.98–0.99 | 0.019* | 0.99    | 0.98–0.99 | 0.028* | 0.99    | 0.99–0.99 | 0.009*   |
| BALF esRAGE, ng/ml | 0.99    | 0.99–0.99 | 0.009* | 0.99    | 0.98–0.99 | 0.041* |

*p < 0.05 Cox proportional hazards model

esRAGE: endogenous secretory receptor for advanced glycation end products, BALF: bronchoalveolar lavage fluid, CI: confidence interval, IPF: idiopathic pulmonary fibrosis, HR: hazard ratio, FVC: forced vital capacity
HMGB1 levels are associated with acute deterioration and poor prognoses for IPF [25, 26]. Additionally, Xia et al. reported that the expression of the S100 protein A4 (S100A4) is increased in mesenchymal progenitor cells in patients with IPF, and increased S100A4 expression is associated with aberrant lung fibrosis in a bleomycin-induced mouse model [27]. Furthermore, esRAGE can act as a decoy receptor for RAGE ligands and inhibit the RAGE/ligand interaction, which may be associated with the IPF disease process [13–15, 28]. Therefore, the present results extend the previous prospective study observations of decreased esRAGE expression in the lungs of patients with IPF [9], and indicate that decreased esRAGE may play a role in the progression of IPF.

The total pool of circulating soluble RAGE (sRAGE) consists of esRAGE and the ectodomain cell-surface RAGE released by metalloproteinases, such as matrix metalloproteinase 9 and a disintegrin and metalloproteinase 10 [29]. In patients with COPD, sRAGE is down-regulated in lung tissue, while esRAGE is not, and reduced circulatory sRAGE is associated with the decline of lung function, while esRAGE is not [9, 30, 31]. However, this study showed that lower levels of circulatory sRAGE were associated with poor survival in patients with IPF, which was in line with the results of previous studies [8, 32], and we confirmed the association of the lung and circulatory esRAGE levels with decreased lung function and poor prognoses. These observations indicate that sRAGE and esRAGE might play different roles in the pathophysiology of lung diseases. However, the present results support the hypothesis that the RAGE/ligand interaction is related to the pathophysiology of IPF, but further investigation is warranted to elucidate causal relationships.

Serum levels of esRAGE were significantly reduced in patients with IPF compared to control subjects. Additionally, there was a significant positive correlation between serum and BALF esRAGE concentrations. These results are in line with those of the previous study elucidating decreased esRAGE expression in the lungs in patients with IPF [9], but its mechanism is still unknown. A possible explanation is that reduced esRAGE levels in IPF could result from lung parenchymal damage, because this study showed that decreased levels of esRAGE in BALF were related to reduced DLco, which was a sensitive indicator of the underlying parenchymal pathology [33–35]. Additionally, although inflammatory cells in the lungs are a potential source of esRAGE [18, 19], there was no correlation between esRAGE levels and differential cell counts in the BALF in this study. Another possible mechanism could be that increased RAGE/ligand interaction in the IPF lung may diminish esRAGE in the circulation [36]. Yet another possibility is that RAGE gene polymorphisms, which modulate the expression of esRAGE, could cause the altered levels of esRAGE in IPF. In order to test this hypothesis, we investigated the association of esRAGE concentrations with two RAGE gene polymorphisms that influence promoter activity (rs1800624 and rs1800625), but there was no significant correlation [20]. Further investigations are needed to elucidate the association between the esRAGE regulatory mechanism and lung fibrosis.

The present study had limitations. It was conducted in a single institution; therefore, the sample size was relatively small, especially with respect to procurement of BALF samples from IPF patients. Additionally, serum levels of esRAGE were significantly lower in patients with IPF than in healthy controls; however, the mean age of IPF patients was around 10 years more than that of healthy controls; further, more smokers were present among patients with IPF than controls. Although esRAGE levels in the serum and BALF were not significantly correlated with age and smoking history in this cohort (data not shown), this could have altered the results. Other studies to confirm the esRAGE circulatory prognostic cut-off level and its predictive value are necessary.

Conclusions
In conclusion, decreased esRAGE levels in both BALF and blood were associated with a poor prognosis in patients with IPF. In particular, serum levels of esRAGE may be a potential prognostic marker reflecting dysregulated RAGE/ligand interactions in the lungs, indicated by lower BALF levels of esRAGE. Finally, further studies are warranted to investigate the role of the RAGE/ligand interaction effect on the progression of IPF.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12931-020-01410-3.

Additional file 1.

Abbreviations
BALF: Bronchoalveolar lavage fluid; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; DLco: Diffusion capacity for carbon monoxide; ELISA: Enzyme-linked immunosorbent assay; esRAGE: Endogenous secretory RAGE; HR: Hazard ratio; HRCT: High-resolution computed tomography; IPF: Idiopathic pulmonary fibrosis; PCR: Polymerase chain reaction; RAGE: Receptor for advanced glycation end products; ROC: Receiver operating characteristic; S100A4: S100 protein A4; SD: Standard deviation; sRAGE: Soluble RAGE; UIP: usual interstitial pneumonia; FVC: Forced vital capacity

Acknowledgements
Not applicable.

Authors’ contributions
KY designed the study, performed the data analysis and interpretation, and wrote the manuscript. HI and WM designed the study. HI also interpreted
the data, and edited the manuscript. SM, SS, YH, TM, SM, TN, SO, HF, HH, and NH collected and prepared samples, interpreted the data and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by the Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare, Japan.

Availability of data and materials
Please contact author for data requests.

Ethics approval and consent to participate
This study was approved by the Ethics Committee of Hiroshima University Hospital (IRB33 and M326), and all participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests (both financial and non-financial) related to this manuscript.

Author details
1Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumimi, Minami-ku, Hiroshima 734-8551, Japan. 2Heart and Lung Centre, Division of Pulmonary Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. 3Department of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. 4Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Received: 29 November 2019 Accepted: 31 May 2020
Published online: 11 June 2020

References
1. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889–901.
2. Huttunen HJ, Fages C, Ruvalca H. Receptor for advanced glycation end products (RAGE)-mediated neutre outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem. 1999;274:19019–24.
3. Demling N, Ehhardt C, Kasper M, Laue M, Knels L, Rieber EP. Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res. 2006;323:475–88.
4. Dahlin K, Mager EM, Allen L, Tigue Z, Goodglick L, Wadehra M, et al. Identification of genes differentially expressed in rat alveolar type I cells. Am J Respir Cell Mol Biol. 2004;31:309–16.
5. Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol. 2010;2010:917108.
6. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1499–61.
7. Raghavi G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/ERS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
8. Yamaguchi K, Iwamoto H, Horimasa Y, Ohshimo S, Fujita A, Harnada H, et al. AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis. Respiriology. 2011;22:965–71.
9. Ishikawa N, Ohmiheier S, Salmenniemi K, Myllamiemi M, Rahman I, Mazur W, et al. Hemoglobin alpha and beta are ubiquitous in the human lung, decline in idiopathic pulmonary fibrosis but not in COPD. Respir Res. 2010;11:123.
10. Manichaikul A, Sun L, Borczuk AC, Onengut-Gumuscu S, Farber EA, Mathai SK, et al. Plasma soluble receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017;14:628–35.
11. Konishi K, Gibson KG, Lindell KO, Richards TJ, Zhang Y, Dhir R, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;180:167–75.
12. Engler JM, Hanford LE, Kaminski N, Tobolowsky JM, Tan RL, Fattman CL, et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol. 2008;172:583–91.
13. Yonemura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097–109.
14. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4:1025–31.
15. Jules J, Maiguel D, Hudson BI. Alternative splicing of the RAGE cytoplasmic domain regulates cell signaling and function. PLoS One. 2013;8:e78267.
16. Hudson BI, Carter AM, Harja E, Kalea AZ, Antiero M, Yang H, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008;22:1572–80.
17. Basta G. Receptor for advanced glycation end products and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196(3–4):21–9.
18. Morbini P, Villa C, Campo I, Zorzetto M, Inghillieri S, Luissetti M. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol. 2006;19:1437–45.
19. Barton DB, Betteridge BC, Earley TD, Curtis CS, Robinson AB, Reynolds PR. Primary alveolar macrophages exposed to diesel particulate matter increase RAGE expression and activate RAGE signaling. Cell Tissue Res. 2014;358:229–38.
20. Hudson BI, Stockland NH, Futers TS, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetes. Diabetes. 2001;50:1505–11.
21. Watanabe M, Horimasa Y, Iwamoto H, Yamaguchi K, Sakamoto S, Masuda T, et al. C-C motif chemokine ligand 15 may be a useful biomarker for predicting the prognosis of patients with chronic hypersensitivity pneumonitis. Respiration. 2019;98:212–20.
22. Miller MR, Crapo R, Hankinson J, Burasco V, Burgos F, Casaburi R, et al. General considerations for lung function testing. Eur Respir J. 2005;26:153–61.
23. Hiyama E, Yokohama T, Hiyama K, Yamakido M, Santo T, Kodama T, et al. Alteration of telomeric repeat length in adult and childhood solid neoplasias. Int J Oncol. 1995;6:13–6.
24. Yamaguchi K, Iwamoto H, Sakamoto S, Horimasa Y, Masuda T, Miyamoto S, et al. AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma. Oncotarget. 2017;8:94382–92.
25. Hamada N, Maeyama T, Kawaguchi T, Yoshimi M, Fukumoto J, Yamada M, et al. The role of high mobility group box 1 in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008;39:440–7.
26. Yamaguchi K, Iwamoto H, Sakamoto S, Horimasa Y, Masuda T, Miyamoto S, et al. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis. Respiriology. 2019;25(3):275.
27. Xia H, Gilbertson A, Herrera J, Racila E, Smith K, Peterson M, et al. Calcium-binding protein S100A4 confers mesenchymal progenitor cell fibrogenicity in idiopathic pulmonary fibrosis. J Clin Invest. 2017;127:2586–97.
28. He M, Kubo H, Ishizawa K, Higab AE, Yamamoto Y, Yamamoto H, et al. The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Phys Lung Cell Mol Phys. 2007;293:L1427–36.
29. Zhang L, Bukulin M, Kojo E, Roth A, Metz W, Fahrenholz F, et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem. 2008;283:35507–16.
30. Gopal P, Schenk C, Schalkwijk CG, Franssen FM, Wouters EF, et al. Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD. Respir Res. 2014;15:24.
31. Iwamoto H, Gao J, Pullikinen Y, Toljamo T, Nieminen P, Mazur W, Soluble receptor for advanced glycation end-products and progression of airway disease. BMC Pulm Med. 2014;14:68.
32. Machahua C, Montes-Worko A, Planes-Cereales L, Buendia-Flores R, Molina-Molina M, Vicens-Zygmunt V. Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis. Respir Res. 2018;19:215.
33. Latsi PI, Du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, et al. Fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:531–7.

34. Collard HR, King TE, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538–42.

35. Egan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005;60:270–3.

36. Renard C, Chappey O, Wautier MP, Nagashima M, Lundh E, Morser J, et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol. 1997;52:54–62.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.